177 related articles for article (PubMed ID: 37108106)
1. Overview of Prostaglandin E2 (PGE2)-Targeting Radiolabelled Imaging Probes from Preclinical Perspective: Lessons Learned and Road Ahead.
Képes Z; Dénes N; Kertész I; Hajdu I; Trencsényi G
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108106
[TBL] [Abstract][Full Text] [Related]
2. In vivo preclinical evaluation of the new
Trencsényi G; Kis A; Szabó JP; Ráti Á; Csige K; Fenyvesi É; Szente L; Malanga M; Méhes G; Emri M; Kertész I; Vecsernyés M; Fenyvesi F; Hajdu I
Int J Pharm; 2020 Feb; 576():118954. PubMed ID: 31935470
[TBL] [Abstract][Full Text] [Related]
3. In vivo investigation of Gallium-68 and Bismuth-205/206 labeled beta cyclodextrin for targeted alpha therapy of prostaglandin E2 receptor-expressing tumors in mice.
Csige K; Szabó JP; Kálmán-Szabó I; Dénes NS; Szikra D; Képes Z; Opposits G; Méhes G; Kertész I; Fenyvesi F; Trencsényi G; Hajdu I
Int J Pharm; 2022 Sep; 625():122132. PubMed ID: 36028082
[TBL] [Abstract][Full Text] [Related]
4. In vivo assessment of tumor targeting potential of
Szabó JP; Csige K; Kálmán-Szabó I; Arató V; Opposits G; Jószai I; Kertész I; Képes Z; Méhes G; Fenyvesi F; Hajdu I; Trencsényi G
Int J Pharm; 2023 Jan; 630():122462. PubMed ID: 36462739
[TBL] [Abstract][Full Text] [Related]
5. Insights into recent preclinical studies on labelled cyclodextrin-based imaging probes: Towards a novel oncological era.
Képes Z; Hajdu I; Fenyvesi F; Trencsényi G
Int J Pharm; 2023 Jun; 640():122978. PubMed ID: 37121492
[TBL] [Abstract][Full Text] [Related]
6. Radiochemical synthesis and preclinical evaluation of
Hajdu I; Angyal J; Szikra D; Kertész I; Malanga M; Fenyvesi É; Szente L; Vecsernyés M; Bácskay I; Váradi J; Fehér P; Ujhelyi Z; Vasvári G; Rusznyák Á; Trencsényi G; Fenyvesi F
Eur J Pharm Sci; 2019 Feb; 128():202-208. PubMed ID: 30521943
[TBL] [Abstract][Full Text] [Related]
7. A Novel Approach for the Control of Inflammatory Pain: Prostaglandin E2 Complexation by Randomly Methylated β-Cyclodextrins.
Sauer RS; Rittner HL; Roewer N; Sohajda T; Shityakov S; Brack A; Broscheit JA
Anesth Analg; 2017 Feb; 124(2):675-685. PubMed ID: 27930390
[TBL] [Abstract][Full Text] [Related]
8. Comparative preclinical evaluation of
Trencsényi G; Dénes N; Nagy G; Kis A; Vida A; Farkas F; Szabó JP; Kovács T; Berényi E; Garai I; Bai P; Hunyadi J; Kertész I
J Pharm Biomed Anal; 2017 May; 139():54-64. PubMed ID: 28273651
[TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of
Satpati D; Sharma R; Sarma HD; Dash A
Chem Biol Drug Des; 2018 Mar; 91(3):781-788. PubMed ID: 29130625
[TBL] [Abstract][Full Text] [Related]
10. PET Probes for Preclinical Imaging of GRPR-Positive Prostate Cancer: Comparative Preclinical Study of [
Kálmán-Szabó I; Szabó JP; Arató V; Dénes N; Opposits G; Jószai I; Kertész I; Képes Z; Fekete A; Szikra D; Hajdu I; Trencsényi G
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077458
[TBL] [Abstract][Full Text] [Related]
11. Increase in negative charge of
Rinne SS; Dahlsson Leitao C; Gentry J; Mitran B; Abouzayed A; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Sci Rep; 2019 Nov; 9(1):17710. PubMed ID: 31776413
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Study on GRPR-Targeted (68)Ga-Probes for PET Imaging of Prostate Cancer.
Sun Y; Ma X; Zhang Z; Sun Z; Loft M; Ding B; Liu C; Xu L; Yang M; Jiang Y; Liu J; Xiao Y; Cheng Z; Hong X
Bioconjug Chem; 2016 Aug; 27(8):1857-64. PubMed ID: 27399868
[TBL] [Abstract][Full Text] [Related]
13.
Mittal S; Sharma R; Mallia MB; Sarma HD
Nucl Med Biol; 2021; 96-97():61-67. PubMed ID: 33838524
[TBL] [Abstract][Full Text] [Related]
14. Preparation and characterization of inclusion complexes of a hemisuccinate ester prodrug of delta9-tetrahydrocannabinol with modified beta-cyclodextrins.
Upadhye SB; Kulkarni SJ; Majumdar S; Avery MA; Gul W; ElSohly MA; Repka MA
AAPS PharmSciTech; 2010 Jun; 11(2):509-17. PubMed ID: 20333489
[TBL] [Abstract][Full Text] [Related]
15. First-In-Human Study Demonstrating Tumor-Angiogenesis by PET/CT Imaging with (68)Ga-NODAGA-THERANOST, a High-Affinity Peptidomimetic for αvβ3 Integrin Receptor Targeting.
Baum RP; Kulkarni HR; Müller D; Satz S; Danthi N; Kim YS; Brechbiel MW
Cancer Biother Radiopharm; 2015 May; 30(4):152-9. PubMed ID: 25945808
[TBL] [Abstract][Full Text] [Related]
16. In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugates.
Fani M; Tamma ML; Nicolas GP; Lasri E; Medina C; Raynal I; Port M; Weber WA; Maecke HR
Mol Pharm; 2012 May; 9(5):1136-45. PubMed ID: 22497506
[TBL] [Abstract][Full Text] [Related]
17. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers.
Persson M; Madsen J; Østergaard S; Ploug M; Kjaer A
Nucl Med Biol; 2012 May; 39(4):560-9. PubMed ID: 22172391
[TBL] [Abstract][Full Text] [Related]
18. [68Ga]NODAGA-RGD for imaging αvβ3 integrin expression.
Knetsch PA; Petrik M; Griessinger CM; Rangger C; Fani M; Kesenheimer C; von Guggenberg E; Pichler BJ; Virgolini I; Decristoforo C; Haubner R
Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1303-12. PubMed ID: 21487838
[TBL] [Abstract][Full Text] [Related]
19. Pilot study of a novel nanobody
Wang Y; Wang C; Huang M; Qin S; Zhao J; Sang S; Zheng M; Bian Y; Huang C; Zhang H; Guo L; Jiang J; Xu C; Dai N; Zheng Y; Han J; Yang M; Xu T; Miao L
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4394-4405. PubMed ID: 35829748
[TBL] [Abstract][Full Text] [Related]
20. Clinical Translation of [
Xavier C; Blykers A; Laoui D; Bolli E; Vaneyken I; Bridoux J; Baudhuin H; Raes G; Everaert H; Movahedi K; Van Ginderachter JA; Devoogdt N; Caveliers V; Lahoutte T; Keyaerts M
Mol Imaging Biol; 2019 Oct; 21(5):898-906. PubMed ID: 30671739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
